Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories

Eli Lilly and Company (NYSE:LLY) announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19.

"Lilly is bringing the full force of our scientific and medical expertise to attack the coronavirus pandemic around the world," said David A. Ricks, Lilly's chairman and chief executive officer. "For more than 140 years Lilly has played a leading role in solving problems in our Indiana home. Today we are marshalling our people and our assets to confront and defeat the novel coronavirus in our state."

Lilly will use its specialized research laboratories to analyze samples taken in Indiana healthcare facilities, including nursing homes and emergency rooms. Assuming the company can continuously access required diagnostic reagents, this should start to expand the state's ability to conduct testing and receive a timely diagnosis of individuals who suspect they may be carrying the virus. As Lilly's testing capacity expands, Lilly and ISDH will work together to maximize the impact of broader testing.

"As the global COVID-19 pandemic has intensified, Lilly has redirected efforts to help solve critical issues – including potential therapeutics, diagnostics and testing," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "Lilly's scientists have been working day and night for several weeks to implement and validate this testing approach, and access or produce the chemical reagents that are in short supply across the country. Lilly's lab meets the required certifications to conduct testing, and we're optimistic in our ability to help accelerate testing."

"At the State Department of Health, we started partnering with Lilly from the early stages to tap into the capabilities of this innovative Indiana company," said Dr. Kris Box, Indiana State Health Commissioner. "We know the magnitude of the impact that advances by Lilly can have on how we diagnose and treat Hoosiers and people worldwide, and we're grateful for Lilly's commitment to help accelerate solutions."

In addition, Lilly is piloting drive through testing that may eventually be able to test patients outside of a healthcare facility to avoid spread of the virus. The company hopes to have additional details in the coming days.

Lilly will not accept money from government agencies, hospitals, insurance companies or patients for conducting or analyzing tests. "This is one contribution we can make to help slow the spread of coronavirus in our community, and this testing will be entirely free," Ricks said.

About Eli Lilly and Company

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. C-LLY

This release contains forward-looking statements regarding Lilly's efforts in regard to the novel coronavirus. These statements are based on management's current expectations, but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.